PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

CSPC Pharmaceutical Group

Status and phase: Completed; Phase 4

Conditions: Lymphoma

Treatments: Drug: PEG-rhG-CSF

Study type: Interventional

Funder types: Industry

Identifiers

NCT02805218

CSPC-PGC-IV-02-1

Details and patient eligibility

About

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.

Enrollment: 410 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with age ≥ 18 years
• diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients
• Karnofsky Performance Status Z70
• life expectancy of at least 8 months
• normal white blood cell count and platelet count
• Written informed consent are acquired

Exclusion criteria

• uncontrolled infection
• pregnancy
• Have accepted any other anti-tumor drug within 4 weeks before anticipated the study
• Other situations that investigators consider as contra-indication for this study

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

410 participants in 1 patient group

PEG-rhG-CSF

Experimental group

Description:

patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy

Treatment:

Drug: PEG-rhG-CSF